The phase 3 clinical program, CORALreef, consists of 3 trials and is likely the first of its kind for an oral PCSK9 inhibitor, according to the study authors.
RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the initiation of the company s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral.
Merck (MRK) Initiates Phase 3 Clinical Program for MK-0616 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.